Drug Profile


Alternative Names: BM 02015; C 3534; C 3535; Demadex; Dilutol; GJ 1090; Isodiur; JDL 464; Luprac; Sutril; Toradiur; Torem; Toresmide; Torrem R; Torsemide; Trasemide; Unat; Zemide

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Christiaens
  • Developer Christiaens; FUJIFILM Toyama Chemical; Laboratorios Novag; Mitsubishi Tanabe Pharma Corporation; Roche
  • Class Antihypertensives; Heart failure therapies; Small molecules; Sulfonamides
  • Mechanism of Action Loop diuretics; Sodium-potassium-chloride symporter inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Heart failure; Hypertension; Kidney disorders; Liver disorders

Most Recent Events

  • 05 Aug 2016 Meda has been acquired by Mylan
  • 24 Mar 2011 Generic equivalent approved in USA for oedema associated with Congestive heart failure, Renal disease or Hepatic disease
  • 15 Aug 2008 Meda acquires Torasemide for Heart failure from Roche
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top